Results 11 to 20 of about 6,414,902 (294)
Strategies for minimal residual disease detection: current perspectives
Blood and Lymphatic Cancer: Targets and Therapy, 2019 Giacomo Andreani, Daniela Cilloni Department of Clinical and Biological Sciences, University of Turin, Turin, Italy Abstract: Currently, the post-remission treatment in acute leukemia is based on the genetic profile of leukemic cells at diagnosis (ie ...
Andreani G, Cilloni D
doaj +1 more source
Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia [PDF]
Haematologica, 2017 Our aim was to improve outcome prediction after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia by combining cytogenetic and molecular data at diagnosis with minimal residual disease assessment by multicolor flow-cytometry at
Betül Oran +17 more
doaj +2 more sources
A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia [PDF]
Haematologica, 2019 A high proportion of patients with acute myeloid leukemia who achieve minimal residual disease negative status ultimately relapse because a fraction of pathological clones remains undetected by standard methods.
Esther Onecha +21 more
doaj +2 more sources
Revista Brasileira de Hematologia e Hemoterapia, 2013 OBJECTIVE To detect markers for minimal residual disease monitoring based on conventional polymerase chain reaction for immunoglobulin, T-cell receptor rearrangements and the Sil-Tal1 deletion in patients with acute lymphocytic leukemia. METHODS Fifty-
Juliana Godoy Assumpcao +8 more
doaj +2 more sources
Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring? [PDF]
The Journal of Liquid BiopsyDespite a significant evolution in treatment strategies for early breast cancer (EBC) patients, up to 30% of them experience recurrence due to occult micrometastasis.
Mara S. Serafini +5 more
doaj +2 more sources
Clinical Medicine Insights: Oncology, 2015 Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and the leading cause of cancer-related death in children and adolescents. Minimal residual disease (MRD) is a strong, independent prognostic factor.
Jitsuda Sitthi-amorn +7 more
doaj +2 more sources
Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse [PDF]
, 2012 This report describes the clinical courses of two acute myeloid leukemia patients. Both had MLL translocations, the first a t(10;11)(p11.2;q23) with MLL-AF10 and the second a t(11;19)(q23;p13.1) with MLL-ELL fusion.
Meyer, Claus +23 more
core +1 more source
Re: Molecular testing to deliver personalised chemotherapy recommendations
BMC Medicine, 2023 Background There is an increasing focus over time on the discovery and validation of biomarkers in cancer medicine, which can inform the identification of patients that are most likely to benefit from treatment, which therapy is most likely to be ...
Peter Gibbs, Wei Hong, Jeanne Tie
doaj +1 more source
Minimal residual disease [PDF]
Current Opinion in Hematology, 1999 Monitoring of residual disease in patients with malignant hematologic disorders has been recognized as an important diagnostic tool for assessment of the response to treatment and the individual risk of relapse. In a number of malignancies, employment of sensitive techniques permitting the identification of tumor cells within a 10(4)-fold or greater ...
openaire +3 more sources
Haematologica, 2019 Minimal (or ‘measurable’) residual disease in acute lymphoblastic leukemia appears to be a prognostic indicator, with potential value in informing individualized treatment decisions.
Renato Bassan +5 more
doaj +1 more source